{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:46Z","timestamp":1792782526819,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Program of National Natural Science Funds (NNSF) of China","award":["8183008"],"award-info":[{"award-number":["8183008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Identifying the temporal pattern of recurrence and prognostic biomarkers would further help improve the efficacy of chimeric antigen receptor (CAR) -T therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined the prognoses of 119 patients after sequential infusion of anti-CD19 and anti-CD22, a cocktail of 2 single-target CAR (CAR19\/22) T cells in an open-label, single-center clinical trial (ChiCTR-OPN-16008526). And we, from a 70-biomarker panel, identified candidate cytokines that might predict the treatment failure, including primary non-response (NR) and early relapse (ER).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In our study, 3 (11.5%) patients with B-cell acute lymphoblastic leukemia (B-ALL) and 9 (12.2%) cases of B-cell non-Hodgkin lymphoma (NHL) failed to respond to sequential CAR19\/22\u00a0T-cell infusion (NR). A total of 11 (42.3%) B-ALL patients and 30 (52.7%) B-NHL patients had relapses during follow-up. Most recurrence events (67.5%) occurred within six months of sequential CAR T-cell infusion (ER). We found that macrophage inflammatory protein (MIP)-3\u03b1 was a highly sensitive and specific prognostic predictor for patients with NR\/ER and those attaining over-6-month remission. Patients who had higher MIP3\u03b1 levels after sequential CAR19\/22\u00a0T-cell infusion had significantly favorable progression-free survival (PFS) than their counterparts with relatively lower MIP3\u03b1 expression. Our experiments demonstrated that MIP3\u03b1 could enhance the therapeutic effect of CAR-T cells by promoting T-cell infiltration into and enriching memory-phenotype T cells in the tumor environment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study showed that relapse occurred mainly within six months after sequential CAR19\/22\u00a0T-cell infusion. Moreover, MIP3\u03b1 could act as a valuable post-infusion biomarker for identifying patients with NR\/ER.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-023-03418-2","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T06:02:32Z","timestamp":1677909752000},"page":"2245-2256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["MIP3\u03b1 as an early prognostic predictor for patients with B-cell malignancies receiving CD19\/CD22-redirected CAR-T cell cocktail therapy"],"prefix":"10.1007","volume":"72","author":[{"given":"Jin","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"issue":"12","key":"3418_CR1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/leu.2017.145","volume":"31","author":"J Pan","year":"2017","unstructured":"Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH et al (2017) High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 31(12):2587\u20132593","journal-title":"Leukemia"},{"issue":"1","key":"3418_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang N, Hu XL, Cao WY, Li CR, Xiao Y, Cao Y et al (2020) Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood 135(1):17\u201327","journal-title":"Blood"},{"issue":"5","key":"3418_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459","journal-title":"N Engl J Med"},{"issue":"21","key":"3418_CR4","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H et al (2021) A phase i study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137(21):2890\u20132901","journal-title":"Blood"},{"issue":"1","key":"3418_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"10299","key":"3418_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD et al (2021) KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. The Lancet 398(10299):491\u2013502","journal-title":"The Lancet"},{"issue":"4","key":"3418_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/cas.14799","volume":"112","author":"Z Guo","year":"2021","unstructured":"Guo Z, Tu S, Yu S, Wu L, Pan W, Chang N et al (2021) Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Cancer Sci 112(4):1357\u20131368","journal-title":"Cancer Sci"},{"issue":"10","key":"3418_CR8","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S et al (2021) CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 27(10):1797\u20131805","journal-title":"Nat Med"},{"issue":"1","key":"3418_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/bjh.16262","volume":"189","author":"B Dholaria","year":"2019","unstructured":"Dholaria B, Savani BN (2019) Allogeneic haematopoietic cell transplantation after CAR T-cell therapy: safe, effective and contentious. Brit J Haematol 189(1):21\u201323","journal-title":"Brit J Haematol"},{"issue":"1","key":"3418_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjh.16339","volume":"189","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen H, Song Y, Tan X, Zhao Y, Liu X et al (2019) Chimeric antigen receptor T-cell therapy as a bridge to haematopoietic stem cell transplantation for refractory\/relapsed B-cell acute lymphoblastic leukemia. Brit J Haematol 189(1):146\u2013152","journal-title":"Brit J Haematol"},{"issue":"5","key":"3418_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36(5):471\u2013482","journal-title":"Cancer Cell"},{"issue":"5","key":"3418_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S et al (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24(5):563\u2013571","journal-title":"Nat Med"},{"issue":"17","key":"3418_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T et al (2019) The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133(17):1876\u20131887","journal-title":"Blood"},{"issue":"5","key":"3418_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","volume":"22","author":"Y Lou","year":"2020","unstructured":"Lou Y, Chen C, Long X, Gu J, Xiao M, Wang D et al (2020) Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus real-time PCR. J Mol Diagn 22(5):699\u2013707","journal-title":"J Mol Diagn"},{"issue":"24","key":"3418_CR15","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA et al (2018) Clinical Pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res 24(24):6175\u20136184","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3418_CR16","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1172\/JCI128743","volume":"129","author":"DM Barrett","year":"2019","unstructured":"Barrett DM, Improving CAR (2019) T cell immunotherapy\u2013mediated remissions for pediatric leukemia. J Clin Investig 129(5):1842\u20131844","journal-title":"J Clin Investig"},{"issue":"1","key":"3418_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","volume":"7","author":"H Luo","year":"2019","unstructured":"Luo H, Wang N, Huang L, Zhou X, Jin J, Li C et al (2019) Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer 7(1):271","journal-title":"J Immunother Cancer"},{"issue":"16","key":"3418_CR18","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J et al (2017) lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol 35(16):1803\u20131813","journal-title":"J Clin Oncol"},{"issue":"6","key":"3418_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679","journal-title":"Cancer Discov"},{"issue":"23","key":"3418_CR20","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","volume":"25","author":"ZX Yan","year":"2019","unstructured":"Yan ZX, Li L, Wang W, OuYang BS, Cheng S, Wang L et al (2019) Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor t cells in refractory b-cell non-Hodgkin\u2019s lymphoma. Clin Cancer Res 25(23):6995\u20137003","journal-title":"Clin Cancer Res"},{"issue":"19","key":"3418_CR21","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K et al (2021) Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137(19):2621\u20132633","journal-title":"Blood"},{"issue":"15","key":"3418_CR22","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.3390\/ijms21155186","volume":"21","author":"S Kadomoto","year":"2020","unstructured":"Kadomoto S, Izumi K, Mizokami A (2020) The CCL20-CCR6 Axis in Cancer Progression. Int J Mol Sci 21(15):5186","journal-title":"Int J Mol Sci"},{"issue":"21","key":"3418_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. Blood 130(21):2295\u20132306","journal-title":"Blood"},{"key":"3418_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN (2019) Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev 34:45\u201355","journal-title":"Blood Rev"},{"issue":"4","key":"3418_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K (2018) IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36(4):346\u2013351","journal-title":"Nat Biotechnol"},{"issue":"25","key":"3418_CR26","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE et al (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113(25):6392\u20136402","journal-title":"Blood"},{"issue":"5","key":"3418_CR27","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y et al (2020) CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol 50(5):712\u2013724","journal-title":"Eur J Immunol"},{"issue":"1","key":"3418_CR28","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M et al (2019) CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun 10(1):4016","journal-title":"Nat Commun"},{"issue":"14","key":"3418_CR29","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina J et al (2011) Expression of a functional ccr2 receptor enhances tumor localization and tumor eradication by retargeted human t cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17(14):4719\u201330","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03418-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T08:06:47Z","timestamp":1686643607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03418-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3418"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03418-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"1 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted upon approval by the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, and all patients provided informed consent in strict accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent for publication was obtained from each patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}